# Study of BC3195 Monotherapy in Patients With Advanced Solid Tumors

> **NCT05957471** · PHASE1 · UNKNOWN · sponsor: **Biocity Biopharmaceutics Co., Ltd.** · enrollment: 27 (estimated)

## Conditions studied

- Locally Advanced or Metastatic Solid Tumors

## Interventions

- **DRUG:** Drug: BC3195 for Injection

## Key facts

- **NCT ID:** NCT05957471
- **Lead sponsor:** Biocity Biopharmaceutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-06-26
- **Primary completion:** 2025-06
- **Final completion:** 2025-06
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2023-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05957471

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05957471, "Study of BC3195 Monotherapy in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT05957471. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*